(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Diffuse lung disease is one of the most common features of systemic sclerosis, and some degree of pulmonary fibrosis is found in the majority of patients postmortem. [37] The etiology of SSc is ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...

Surrozen, Inc. ('Surrozen” or the 'Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced ...

Timely intervention in oncology is critical for improving survival rates, disease progression, and quality of life. Delays in treatment can result in advanced disease stages, reduced treatment ...

"I love offering this innovative, minimally invasive technique for treating Haglund's Syndrome and insertional Achilles pathology," said Dr. Vesely ... of ISM001-055 for the Treatment of Idiopathic ...